Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FEMALE-PH

Financiado

Mending sex differences: Unravelling the female predominance in pulmonary hypert...

Mending sex differences: Unravelling the female predominance in pulmonary hypertension Pulmonary hypertension (PH) is a rare but progressive fatal disease characterized by accumulation of persistently activated cell types in the pulmonary vascular wall exhibiting abnormal expression of genes driving proliferation, i... ver más

29/02/2028

STICHTING AMSTERDA...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-02-10

ERC-2022-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

STICHTING AMSTERDAM UMC

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-096827-B-I00 MODULACION FARMACOLOGICA DE LA SEÑALIZACION REDOX EN REMODEL... 97K€ Cerrado

PID2019-104406RB-I00 EFECTOS DEL HUMO DE TABACO EN LA VASCULATURA PULMONAR. MECAN... 97K€ Cerrado

PID2020-117939RB-I00 CANALES KV COMO DIANAS FARMACOLOGICAS EN LA HIPERTENSION ART... 213K€ Cerrado

SAF2009-08913 MODULACION FARMACOLOGICA DEL REMODELADO DE VIAS AEREAS Y VAS... 242K€ Cerrado

PID2021-123167OB-I00 NUEVAS DIANAS Y ESTRATEGIAS TERPAEUTICAS EN LA HIPERTENSION... 200K€ Cerrado

SAF2014-55399-R MICRORNAS IMPLICADOS EN DISFUNCION VASCULAR PULMONAR: IMPLIC... 133K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-02-10
Fecha Fin: 2028-02-29

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Pulmonary hypertension (PH) is a rare but progressive fatal disease characterized by accumulation of persistently activated cell types in the pulmonary vascular wall exhibiting abnormal expression of genes driving proliferation, inflammation, and metabolism. The currently used vasodilatory therapies have little or no impact on this activated phenotype and therefore offer no cure or even substantial survival benefit. PH has a high female predominance (3:1 to 9:1). This proposal aims to understand the mechanism behind the high female predominance to identify novel therapeutic targets to attenuate disease progression in male and female PH patients. Female predominance can be linked to sex hormones and/or incomplete X chromosome inactivation (XCI) leading to biallelic expression of immunoinflammatory and metabolic genes. To understand the impact of oestrogen and androgen signalling on abnormal vascular remodelling in PH, I will develop a unique opposite-sex lung transplantation rat model, identify oestrogen metabolites in a large set of patient serum samples and explore their biological relevance using pulmonary vascular cells from male and female PH patients in cell-based assays. Preliminary experiments suggest there is incomplete XCI in PH. I propose to combine sequencing and molecular studies to extensively characterize the impact of incomplete XCI on the physiology of male and female PAH cells and identify genes and druggable targets regulating incomplete XCI in PH. Finally, I will explore a novel pulmonary endothelium-specific drug delivery method to deliver identified promising genes/compounds to selectively inhibit the activated pulmonary vasculature thereby minimalizing side effects compared to current delivery methods. Together, this high risk-high gain study will dissect the molecular mechanisms underlying the unresolved female predominance in PH and offer novel pulmonary endothelium-specific therapies for both male and female PH patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores